-
In the first half of this year, almost half (48%) of ambulatory organizations and 68% of office-based surgical practices accredited by The Joint Commission were not in compliance with HR.02.01.03: The organization grants initial, renewed, or revised clinical privileges to individuals who are permitted by law and the organization to practice independently.
-
The Chinese man struggled to understand what his American health care provider was saying. The patient barely spoke English. The provider threw up his hands in frustration and sitalicsid, "He just doesn't get it."
-
A reader responded to my column on getting patients in 45 minutes before surgery. Her response: "What is the name of your planet?
-
With the recent release of the HITECH rule's language on breach notification, managers can be left wondering when they have to notify after a breach of protected health information (PHI) in violation of the Health Insurance Portability and Accountability Act (HIPAA).
-
-
In women, insomnia was not associated with increased risk of death, regardless of sleep duration. In men, mortality risk was significantly increased only in insomniacs who slept less than 6 hours and who were diabetic or hypertensive at baseline.
-
Although there are few studies that specifically look at the elderly, this review provides useful information on the diagnosis and treatment of acute exacerbation of COPD and chronic bronchitis.
-
Dietary pattern analysis of elderly subjects followed over at least 4 years showed lower risk for developing Alzheimer's disease when there was higher intake of nuts, fish, tomatoes, poultry, salad dressing, cruciferous vegetables, fruits, and dark and green leafy vegetables, along with lower intake of high-fat diary products, red meat, organ meat, and butter.
-
A third inhaled corticosteroid and long-acting beta-agonist combination has been approved by the FDA, joining currently marked combinations fluticasone/salmeterol (Advair Diskus®) and budesonide/formoterol (Symbicort®). Mometasone furoate and formoterol fumarate is marketed by Schering as Dulera®
-
Clinicians are increasingly presented with the tasks of addressing not only a burgeoning population of type 2 diabetics, but an equally voluminous group of prediabetics.
